There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials and policy / regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, the newest position statement from February 2021 attempts to address these issues and recommend prospective genotyping test prior to anticoagulants, antipalets, statins and betablockers.

European Heart Journal – Cardiovascular Pharmacotherapy, pvab018,

Share this post